Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2012 | Review Article

Rationale for the use of radiolabelled peptides in diagnosis and therapy

Authors: K. P. Koopmans, A. W. J. M. Glaudemans

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2012

Abstract

Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory peptides, but penetrating peptides are also being developed. Peptides for imaging inflammatory and infectious diseases include regulatory peptides, antimicrobial peptides and others. In conclusion, for the imaging of oncological, imflammatory and infectious diseases, many promising peptides are being developed. The ideal peptide probe is characterized by rapid and specific target localization and binding with a high tumour-to-background ratio.

Signore A, Mather SJ, Piaggio G, Malviya G, Dierckx RA. Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. Chem Rev. 2010;110:3112–45.PubMedCrossRef

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93.PubMedCrossRef

Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010;110:3087–111.PubMedCrossRef

Krohn KA. The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images. Nucl Med Biol. 2001;28:477–83.PubMedCrossRef

Breeman WA, Hofland LJ, de Jong M. Evaluation of radiolabelled bombesin analogues for receptor targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658–63.PubMedCrossRef

Eberle AN, Mild G. Receptor-mediated tumor targeting with peptides. Part I. General principles and methods. J Recept Signal Transduct Res. 2009;29:1–37.PubMedCrossRef

Ferro-Flores G, Ramírez Fde M, Meléndez-Alafort L, Santos-Cuevas CL. Peptides for in vivo target-specific cancer imaging. Mini Rev Med Chem. 2010;10:87–97.PubMedCrossRef

Mankoff DA, Link JM, Linden HM, Sundararanjan L, Krohn KA. Tumor receptor imaging. J Nucl Med. 2008;49:149s–63s.PubMedCrossRef

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.PubMedCrossRef

10.

Nanda PK, Lane SR, Retzloff LB, Pandey US, Smith CJ. Radiolabeled regulatory peptides for imaging and therapy. Curr Opin Endocrinol Diabetes Obes. 2010;17:69–76.PubMed

11.

Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40:209–18.PubMedCrossRef

12.

Torres Martin de Rosales R, Arstad E, Blower PJ. Nuclear imaging of molecular processes in cancer. Target Oncol. 2009;4:183–97.PubMedCrossRef

13.

Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med. 2011;52:841–4.PubMedCrossRef

14.

de Visser M, Verwijnen SM, de Jong M. Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother Radiopharm. 2008;23:137–57.PubMedCrossRef

15.

Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707–15.PubMedCrossRef

16.

Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3,Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med. 2005;46:1561–9.PubMed

17.

Weckberger G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999–1017.CrossRef

18.

Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem. 2008;8:186–99.PubMedCrossRef

19.

Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28–47.PubMedCrossRef

20.

Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–86.PubMed

21.

Wank SA, Pisegna JR, de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A. 1992;89:8691–5.PubMedCrossRef

22.

Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992;89:3605–9.PubMedCrossRef

23.

Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029–44.PubMed

24.

Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods. 2009;48:161–77PubMedCrossRef

25.

Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318–26.PubMedCrossRef

26.

Kuil J, Velders AH, van Leeuwen FW. Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. Bioconjug Chem. 2010;21:1709–19.PubMedCrossRef

27.

Shetzline MA, Walker JK, Valenzano KJ, Premont RT. Vasoactive intestinal polypeptide type-1 receptor regulation. Desensitization, phosphorylation, and sequestration. J Biol Chem. 2002;277:25519–26.PubMedCrossRef

28.

Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Prasad S, et al. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med. 2004;45:1381–9.PubMed

29.

Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: in vitro/in vivo evaluation. Regul Pept. 2007;144:91–100.PubMedCrossRef

30.

Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736–43.PubMedCrossRef

31.

Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. New Engl J Med. 2008;359:766–8.PubMedCrossRef

32.

Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398–405.PubMedCrossRef

33.

Reubi JC, Waser B, Friess H, Büchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546–50.PubMedCrossRef

34.

Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66:6243–9.PubMedCrossRef

35.

de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–9.PubMedCrossRef

36.

Maes V, Garcia-Garayoa E, Bläuenstein P, Tourwé D. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem. 2006;49:1833–6.PubMedCrossRef

37.

García-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, et al. Preclinical evaluation of a new, stabilized neurotensin(8-13) pseudopeptide radiolabeled with (99m)Tc. J Nucl Med. 2002;43:374–83.PubMed

38.

Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med. 2003;44:1649–54.PubMed

39.

Miao Y, Quinn TP. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci. 2007;12:4514–24.PubMedCrossRef

40.

Tatro JB, Wen Z, Entwistle ML, Atkins MB, Smith TJ, Reichlin S, et al. Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 1992;52:2545–8.PubMed

41.

Yang J, Guo H, Gallazzi F, Berwick M, Padilla RS, Miao Y. Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjug Chem. 2009;20:1634–42.PubMedCrossRef

42.

Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des. 2008;14:2415–47.PubMedCrossRef

43.

Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, et al. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical. Int J Pharm. 2009;375:75–83.PubMedCrossRef

44.

Signore A, Glaudemans AW. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. Ann Nucl Med. 2011;25:681–700PubMedCrossRef

45.

Van de Wiele C, Signore A, Dierckx RA. Peptide receptor imaging: advances in the diagnosis of pulmonary diseases. Am J Respir Med. 2002;1:177–83.PubMed

46.

Migliore A, Signore A, Capuano A, Bizzi E, Massafra U, Vacca E, et al. Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. Eur Rev Med Pharmacol Sci. 2008;12:127–30.PubMed

47.

Duet M, Lioté F. Somatostatin and somatostatin analog scintigraphy: any benefits for rheumatology patients? Joint Bone Spine. 2004;71:530–5.PubMedCrossRef

48.

Postema PT, Kwekkeboom DJ, van Hagen PM, Krenning EP. Somatostatin-receptor scintigraphy in Graves’ orbitopathy. Eur J Nucl Med. 1996;23:615–7.PubMedCrossRef

49.

Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, et al. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy. J Clin Endocrinol Metab. 2005;90:2440–4.PubMedCrossRef

50.

Chianelli M, Boerman OC, Malviya G, Galli F, Oyen WJ, Signore A. Receptor binding ligands to image infection. Curr Pharm Des. 2008;14:3316–25.CrossRef

51.

Melendez-Alafort L, Rodriguez-Cortes J, Ferro-Flores G, de Murphy CA, Herrera-Rodriguez R, Mitsoura E. Biokinetics of Tc-99m-UBI 29-41 in humans. Nucl Med Biol. 2004;31:373–9.PubMedCrossRef

52.

Welling MM, Nibeering PH, Paulusma-Annema A, Hiemstra PS, Pauwels EK, Calame W. Imaging of bacterial infections with Tc-99m-labeled human neutrophil peptide-1. J Nucl Med. 1999;40:2073–80.PubMed

53.

Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammation. Eur J Nucl Med. 2000;27:292–301.PubMedCrossRef

54.

Paul C, Peers SH, Woodhouse LE, Thornback JR, Goodbody AE, Bolton C. The detection and quantification of inflammation in the central nervous system during experimental allergic encephalomyelitis using the radiopharmaceutical 99mTc-RP128. J Neurosci Methods. 2000;98:83–90.PubMedCrossRef

55.

Caveliers V, Goodbody AE, Tran LL, Peers SH, Thornback JR, Bossuyt A. Evaluation of 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med. 2001;42:154–61.PubMed

56.

Palestro CJ, Weiland FL, Seabold JE, Valdivia S, Tomas MB, Moyer BR, et al. Localizing infection with a technetium-99m-labeled peptide: initial results. Nucl Med Commun. 2001;22:695–701.PubMedCrossRef

57.

Breeman WA, VanHagen MP, Visser-Wisselaar HA, van der Pluijm ME, Koper JW, Setyono-Han B, et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-ARG1]substance P. J Nucl Med. 1996;37:108–17.PubMed

58.

van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med. 1996;23:1508–13.PubMedCrossRef

Title: Rationale for the use of radiolabelled peptides in diagnosis and therapy
Authors: K. P. Koopmans
A. W. J. M. Glaudemans
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-2038-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rationale for the use of radiolabelled peptides in diagnosis and therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2012

111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs

Somatostatin receptor SPECT

Radiolabelled RGD peptides for imaging and therapy

Gallium-labelled peptides for imaging of inflammation

Yttrium-labelled peptides for therapy of NET

Feasibility and availability of 68Ga-labelled peptides